Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

Paul E Goss, James N Ingle, Joseph L Pater, Silvana Martino, Nicholas J Robert, Hyman B Muss, Martine J Piccart, Monica Castiglione, Lois E Shepherd, Kathleen I Pritchard, Robert B Livingston, Nancy E Davidson, Larry Norton, Edith A Perez, Jeffrey S Abrams, David A Cameron, Michael J Palmer, Dongsheng Tu

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

The National Cancer Institute of Canada Clinical Trials Group MA.17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in postmenopausal hormone receptor-positive early-stage breast cancer. When the trial was unblinded, patients who received placebo (PLAC) were offered LET.
Original languageEnglish
Pages (from-to)1948-55
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number12
DOIs
Publication statusPublished - 2008

Keywords / Materials (for Non-textual outputs)

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Disease-Free Survival
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Middle Aged
  • Neoplasms, Hormone-Dependent
  • Nitriles
  • Placebos
  • Postmenopause
  • Tamoxifen
  • Treatment Outcome
  • Triazoles

Fingerprint

Dive into the research topics of 'Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen'. Together they form a unique fingerprint.

Cite this